Global Nicotinamide Phosphoribosyl Transferase Market Size By Type (STF-118804, P7-C3A20), By Application (Research Center, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Nicotinamide Phosphoribosyl Transferase (NAMPT) Market was valued at USD 426.5 million in 2023 and is expected to reach USD 928.4 million by 2031, growing at a robust CAGR of 10.1% during the forecast period from 2023 to 2031. NAMPT plays a pivotal role in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in cellular metabolism. The increasing interest in NAD+ metabolism as a therapeutic strategy in oncology, metabolic disorders, and neurodegenerative diseases is significantly driving market growth. Ongoing research into NAMPT inhibitors and enhancers, along with rising R&D investments, is opening new frontiers in targeted therapy and regenerative medicine.

Drivers:

1. Rising Interest in NAD+ Metabolism:

Growing research into cellular aging and metabolic pathways is fueling demand for NAMPT-targeted therapies. The association between NAD+ decline and age-related diseases has positioned NAMPT modulation as a potential anti-aging and therapeutic solution.

2. Expanding Oncology Applications:

NAMPT inhibitors have shown promise in preclinical and clinical trials for several cancers, including leukemia, lymphoma, and solid tumors. This expands the clinical interest in targeting NAMPT for oncology drug development.

3. Growth in Personalized Medicine and Biomarker Discovery:

NAMPT expression is emerging as a potential biomarker in certain cancers, aiding in patient stratification and targeted therapy—enhancing the role of NAMPT in precision medicine.

Restraints:

1. Safety and Toxicity Challenges in NAMPT Inhibitors:

Despite their potential, NAMPT inhibitors have been associated with systemic toxicity and dose-limiting side effects, particularly in cancer treatment, which could limit adoption.

2. Regulatory and Developmental Hurdles:

The complexity of developing NAMPT-targeted therapies, including stringent regulatory requirements and limited historical data, may delay approvals and market entry.

Opportunity:

1. Expansion in Neurodegenerative and Metabolic Disorder Therapeutics:

Recent studies suggest NAMPT modulation may benefit conditions such as Alzheimer’s disease, Parkinson’s, and type 2 diabetes—offering new market avenues beyond oncology.

2. Rise in Biotech Collaborations and Licensing Deals:

The NAMPT market is witnessing increasing collaboration between pharmaceutical companies and biotech startups to develop innovative compounds, accelerating clinical pipelines and technology access.

Market by System Type Insights:

The Inhibitor-based NAMPT Therapeutics segment dominated the market in 2023 due to its promising potential in oncology. NAMPT inhibitors like FK866 and OT-82 are leading candidates in clinical development, particularly for hematologic malignancies. Meanwhile, the Enhancer-based Therapeutics segment is gaining momentum, particularly for applications in aging and metabolic health, and is projected to be the fastest-growing during the forecast period.

Market by End-use Insights:

Biopharmaceutical Companies accounted for the largest revenue share in 2023. Their heavy investment in oncology and regenerative medicine pipelines, along with strong R&D capabilities, makes them the key contributors to the NAMPT market. Academic & Research Institutions are also significant players, particularly in early-stage research and preclinical trials, fueling innovation and new discovery pathways.

Market by Regional Insights:

North America led the global NAMPT market in 2023, driven by advanced healthcare infrastructure, substantial funding for cancer research, and active clinical trial networks. Europe follows closely with strong pharmaceutical R&D support and regulatory approvals. However, the Asia-Pacific region is expected to grow at the fastest CAGR, fueled by rising healthcare investment, growing biotech sectors in China and India, and increasing awareness of age-related diseases.

Competitive Scenario:

Key companies operating in the global NAMPT market include Selleck Chemicals, ApexBio, Calithera Biosciences, Genentech (Roche), Chugai Pharmaceutical, Genzada Pharmaceuticals, Kyowa Kirin, and Novartis. Strategic collaborations, novel molecule discoveries, and clinical trial advancements are common growth tactics. Notable developments include:

2023: Calithera Biosciences presented promising Phase 1/2 data on NAMPT inhibitors for relapsed leukemia.

2024: Genzada Pharmaceuticals received FDA Fast Track Designation for its NAMPT-targeted therapy in advanced ovarian cancer.

2025: Kyowa Kirin and a major U.S. academic institute launched a joint program to explore NAMPT modulation for neurodegenerative diseases.

Scope of Work – Global Nicotinamide Phosphoribosyl Transferase (NAMPT) Market

Key Market Developments:

2023: Calithera Biosciences presented new clinical data for its novel NAMPT inhibitor with reduced toxicity profile.

2024: Novartis initiated a Phase II trial evaluating NAMPT modulation in combination with immune checkpoint inhibitors.

2025: ApexBio expanded its NAMPT chemical compound catalog, supporting academic research globally.

FAQs:

1. What is the current market size of the Global Nicotinamide Phosphoribosyl Transferase Market?

The market size was valued at USD 426.5 million in 2023.

2. What is the major growth driver of the Global Nicotinamide Phosphoribosyl Transferase Market?

The primary growth driver is the rising interest in NAD+ metabolism and its applications in oncology and aging.

3. Which is the largest region during the forecast period in the Global Nicotinamide Phosphoribosyl Transferase Market?

North America holds the largest share, while Asia-Pacific is the fastest-growing region.

4. Which segment accounted for the largest market share in the Global Nicotinamide Phosphoribosyl Transferase Market?

The Inhibitor-based Therapeutics segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Nicotinamide Phosphoribosyl Transferase Market?

Key players include Calithera Biosciences, ApexBio, Genentech, Kyowa Kirin, and Genzada Pharmaceuticals.